| Autor: |
Möricke, A., Zimmermann, M., Reiter, A., Henze, G., Schrauder, A., Gadner, H., Ludwig, W. D., Ritter, J., Harbott, J., Mann, G., Klingebiel, T., Zintl, F., Niemeyer, C., Kremens, B., Niggli, F., Niethammer, D., Welte, K., Stanulla, M., Odenwald, E., Riehm, H. |
| Předmět: |
|
| Zdroj: |
Leukemia (08876924); Feb2010, Vol. 24 Issue 2, p265-284, 20p, 1 Diagram, 6 Charts, 5 Graphs |
| Abstrakt: |
Between 1981 and 2000, 6609 children (<18 years of age) were treated in five consecutive trials of the Berlin–Frankfurt–Münster (BFM) study group for childhood acute lymphoblastic leukemia (ALL). Patients were treated in up to 82 centers in Germany, Austria and Switzerland. Probability of 10-year event-free survival (EFS) (survival) improved from 65% (77%) in study ALL-BFM 81 to 78% (85%) in ALL-BFM 95. In parallel to relapse reduction, major efforts focused on reducing acute and late toxicity through advanced risk adaptation of treatment. The major findings derived from these ALL-BFM trials were as follows: (1) preventive cranial radiotherapy could be safely reduced to 12 Gy in T-ALL and high-risk (HR) ALL patients, and eliminated in non- HR non-T-ALL patients, if it was replaced by high-dose and intrathecal (IT) MTX; (2) omission of delayed re-intensification severely impaired outcome of low-risk patients; (3) 6-month-less maintenance therapy caused an increase in systemic relapses; (4) slow response to an initial 7-day prednisone window was identified as adverse prognostic factor; (5) condensed induction therapy resulted in significant improvement of outcome; (6) the daunorubicin dose in induction could be safely reduced in low-risk patients and (7) intensification of consolidation/re-intensification treatment led to considerable improvement of outcome in HR patients. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
